Vertex aims for broad kidney disease label ahead of key readout next year

Data ReadoutpositiveinaxaplinPositive

AI Analysis

Summary

Vertex Pharmaceuticals reported positive interim data for inaxaplin in kidney disease, showing improvement in urine test measures across two patient populations ahead of a pivotal readout expected next year.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

improved measures on urine test in two different patient populations

Importance:6/10

Sentiment:

0.60

kidney diseaseclinical trialnephrologydata readout

Related Companies

$VRTX

Read the original article

Published by Endpoints News on September 22, 2026 5:45 PM

Read Original